U.K., pharma industry strike deal for how the NHS pays for medicines; The FDA is at a crossroads on cell and gene therapies

Taking stock of the drug industry, from the lab to the medicine chest

November 20, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Christine Kao/STAT, Adobe STAT+ | U.K., pharma industry strike deal for how the NHS pays for medicines The deal is meant to save the NHS billions of pounds while fostering the industry and promoting access to new medicines. By Andrew Joseph Opinion: The FDA is at a crossroads on cell and gene therapies Former Sen. Richard Burr: "The FDA has an opportunity to transform its oversight of cell and gene therapies and deliver on promises made." By Richard Burr STAT+ | What Eli Lilly's Zepbound reveals about the intricate process of naming drugs today Marketing the same drug with two names is not unheard of: Prozac and Sarafem, Latisse and Lumigan, Eylea and Zaltrap. Here's why it happens. By Annalisa Merelli

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser